Oncology/Hematology Market Research Reports & Industry Analysis
Oncology/Hematology Industry Research & Market Reports
-
Brachytherapy
... 4.3% over the analysis period 2024-2030. High Dose Rate, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.6 Billion by the end of the analysis period. ... Read More
-
Cervical Cancer Endoscopic Devices
... 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Optical Colposcopes, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$668.1 Million by the ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Endometrial Cancer Treatment
... at a CAGR of 5.0% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$31.3 Billion by the end of the ... Read More
-
Hematology Testing Products
... at a CAGR of 4.4% over the analysis period 2024-2030. Instruments & Software, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$9.8 Billion by the end ... Read More
-
Non-Small Cell Lung Cancer (NSCLC) Therapeutics
... reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach ... Read More
-
Cancer Registry Software
... at a CAGR of 9.6% over the analysis period 2024-2030. Standalone, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$116.6 Million by the end of the ... Read More
-
Breakthrough Therapy (BT) Designation
... 2030, growing at a CAGR of 15.7% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 16.5% CAGR and reach US$138.3 Billion by the end ... Read More
-
Breast Cancer Liquid Biopsy
... 2030, growing at a CAGR of 21.9% over the analysis period 2024-2030. Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.4% CAGR and reach US$819.3 Million by the ... Read More
-
Cervical Cancer Treatment
... at a CAGR of 6.0% over the analysis period 2024-2030. Squamous Cell Carcinoma (SCC), one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$9.1 Billion by the ... Read More
-
Hemato Oncology Testing
... at a CAGR of 16.5% over the analysis period 2024-2030. Services, one of the segments analyzed in the report, is expected to record a 15.6% CAGR and reach US$8.6 Billion by the end of the ... Read More
-
Prostate Cancer Diagnostics
... at a CAGR of 13.3% over the analysis period 2024-2030. Preliminary, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$10.0 Billion by the end of the ... Read More
-
Cancer Vaccines
... CAGR of 9.3% over the analysis period 2024-2030. Preventive Vaccine, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$7.6 Billion by the end of the analysis ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Head and Neck Cancer Therapeutics
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. PD Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$2.5 Billion ... Read More
-
Patient Derived Xenograft / PDX Models
... reach US$1.0 Billion by 2030, growing at a CAGR of 14.3% over the analysis period 2024-2030. Mice PDX Models, one of the segments analyzed in the report, is expected to record a 14.9% CAGR and ... Read More
-
Kidney Cancer Drugs
... at a CAGR of 4.8% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$5.6 Billion by the end of ... Read More
-
Lung Cancer Diagnostics
... at a CAGR of 7.8% over the analysis period 2024-2030. Imaging Tests, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$2.3 Billion by the end of ... Read More
-
Cancer Insurance Global Market Report 2025
... is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly global perspective with the ... Read More
-
Breast Cancer Screening
... at a CAGR of 5.1% over the analysis period 2024-2030. Imaging Test, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$4.8 Billion by the end of ... Read More
-
Chemotherapy-induced Nausea and Vomiting Drugs
... Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Serotonin Receptor Antagonist, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$2.0 ... Read More
-
Malignant Mesothelioma
... CAGR of 6.2% over the analysis period 2024-2030. Premetrexed & Combination, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$518.6 Million by the end of the ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
NDDS in Cancer Therapy
... 2030, growing at a CAGR of 20.7% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 20.6% CAGR and reach US$67.8 Billion by the end ... Read More
-
Hematological Malignancies
... CAGR of 6.2% over the analysis period 2024-2030. Leukemia, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$33.3 Billion by the end of the analysis period. ... Read More
Research Assistance
